Establishment of a liquid chromatography tandem mass spectrometry method for vitamin D metabolites to detect 24-hydroxylase deficiency



KIMCL GRAZ Medical University of Graz

Sieglinde Zelzer¹, Andreas Meinitzer¹, Dietmar Enko^{1,2}, Sebastian Simstich¹, Karin Amrein^{3,4}, Walter Goessler⁵, Markus Herrmann¹

¹Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria; ²Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Hochsteiermark, Austria; ³Thyroid Endocrinology Osteoporosis Institute Dobnig, Graz, Austria; ⁴Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Austria; ⁵Institute of Chemistry, University of Graz, Austria

E-Mail: sieglinde.zelzer@medunigraz.at

Introduction

Determination of 25-hydroxyvitamin D (25(OH)D) is recommended for the assessment of Vitamin D status. Concentrations in serum samples >100 nmol/L are considered desireable. However, in 24-hydroxylase deficient individuals higher than 100 nmol/L may be critical. The resulting endogenous Vitamin D excess can cause hypercalcemia and nephrocalcinosis with corresponding symptoms [1]. Simultaneous measurement of $25(OH)D_3$, 25-hydroxyvitamin D₂ ($25(OH)D_2$), and 24,25-dihydroxyvitamin D₃ ($24,25(OH)_2D_3$) may help to identify affected individuals. Therefore, we established a liquid-chromatography-tandem-mass-spectrometry (LC-MS/MS system) method for determination of three Vitamin D metabolites.

Methods & patients

The method consists of protein precipitation followed by liquid-liquid-extraction and subsequent derivatization with 4-Phenyl-1,2,4-triazole-3,5-dione (PTAD) [2]. Samples were separated on an Agilent HPLC 1260 system using a Zorbax C18Eclipse column and a gradient elution. The eluate was introduced into a Sciex 4500 MS/MS instrument for the detection of the three metabolites within 17 min. Analytical performance was assessed by determining linearity, limit of detection (LOD), limit of quantification (LOQ), imprecision and recovery. Accuracy was analyzed by method comparison with a commercial 25(OH)Vitamin D LC-MS/MS method (Recipe) at the Department of Clinical Pathology at Bolzano Hospital (Italy), with a validated in-house LC-MS/MS method from University of Liege (Belgium) and samples from the Vitamin D External Quality Assessment Scheme (DEQAS) which is traceable to the National Institute for Standards and Technology (NIST) [3,4]. In addition, the method was tested on four sera from patients that were referred to our laboratory, because of 25-hydroxyvitamin D concentration >100 nmol/L.

Results

The used transitions (m/z, mass to charge ratios) and analytical performances are summarized in Table 1. Results of the method comparison are shown in Table 2. Serum concentrations of all vitamin D metabolites obtained for all four patients are summarized in Table 3. Representative chromatograms for all vitamin D metabolites from the serum sample with 24-hydroxylase deficiency are shown in Figure 1 (A-C). Figure 2 shows the separation of the $24,25(OH)_2D_3$ and $25,26(OH)_2D_3$ metabolite and Figure 3 represents a possible physiolocial pathway in patient with a 24-hydroxylase defect.

In ten DEQAS samples the results for all three metabolites were within the allowable limits from the NIST target value.

Table 2. Results of the Bland and Altman difference plot with the in-house method and the commercial 25-OH-Vitamin D2/D3 LC-MS/MS assay from RECIPE for $25(OH)D_3$, and $25(OH)D_2$ (Department of Clinical Pathology at Bolzano Hospital (Italy)) and with the in-house method and the validated in-house LC-MS/MS method at the Department of Clinical Chemistry, University of Liege (Belgium) for $24,25(OH)_2D_3$

	25/OH)D ₃	25(OH)D ₂	24,25(OH) ₂ D ₃
Mean difference	-0.8798	-2.0260	-0.2335
95 % CI	-22.344 - 20.585	-25.1476 - 21.096	-1.7924 to 1.3254
Intercept	-1.842 - 9.303	-0.8333 - 10.200	-0.7975 - 1.098
Slope	0.79-1.03	0.76-1.00	0.72–1.14
CI = confidents interval			



Table 1. Performance characteristics of the Vitamin D in-house LC-MS/MS method

	25(OH)D ₃	25(OH)D ₂	24,25(OH) ₂ D ₃
m/z ratio	558.4 / 298.1	570.2 / 298.1	574.2 / 298.1
Linear range (nmol/L)	7.8 - 250	1.5 - 48	1.5 - 48
Correlation factor (r ²)	0.999	0.997	0.998
Intraday assay (CV %)	1.8 - 10.4	3.5 – 7.3	5.3 - 8.3
Interday assay (CV %)	2.9 - 14.3	1.5 – 13.6	1.2 - 12.1
LoD (nmol/L)	1.5	0.3	0.3
LoQ (nmol/L)	3.1	1.0	1.0
Recovery (%)	72.2	73.1	69.3

m/z = mass to charge ratio; LoD = limit of detection; LoQ = limit of quantification; CI = confidents interval Imprecision was assessed using two serum samples, commercial control material from RECIPE and in-house prepared calibrators.

Summary

- Valitation of this in-house method showed adequat analytical performance with good sensitivity, specificity, accuracy and precision for $25(OH)D_3$, $25(OH)D_2$ and $24,25(OH)_2D_3$ Vitamin D metabolites.
- The performance in the DQAS programm confirmed acceptable accuracy for all Vitamin D metabolites tested.
- The clinical utility of this method has been confirmed in a patient with 24-hydroxylase deficiency.



Figure 1. Chromatograms of Vitamin D metabolites in a patient with 24-hydroxylase deficiency. A) $25(OH)D_3$ concentration: 166 nmol/L (normal range: 50-100 nmol/L); B) $25(OH)D_2$ concentration: 3.3 nmol/L (2-50nmol/L); C) $24,25(OH)_2D_3$ concentration: 0.16 nmol/L (2-50 nmol/L)



Patient	25(OH)D₃ [nmol/L]	25(OH)D₃ [nmol/L]	24,25(OH) ₂ D ₃ [nmol/L]	Ca [mmol/L
1	166	3.3	0.16	3.7
2	445	0.3	6.5	2.5
3	182	1.04	11.1	2.4
4	134	1.77	10.9	2.4

LITERATURE

(1) Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. The New England Journal of Medicine. 2011;365(5):410-21.

(2) Laha TJ, Strathmann FG, Wang Z, de Boer IH, Thummel KE and Hoofnagele AN. Cross-reactivity for Immunoaffinity Purification of Analytes prior to Multiplexed Liquid Chromatography-Tandem Mass Spectrometry. Clinical Chemistry. 2012;58:(12)1711-16.
(3) Binklay N. Sampos CT: Vitamin D. Standardization Program (VDSP). Standardizing vitamin D assays: the way forward. Journal of Bona

(3) Binkley N, Sempos CT; Vitamin D Standardization Program (VDSP). Standardizing vitamin D assays: the way forward. Journal of Bone and Mineral Research. 2014;29(8):1709-14.

(4) Zelzer S, Goessler W, Herrmann M. Measurement of vitamin D metabolites by mass spectrometry, an analytical challenge. Journal of Laboratory and Precision Medicine. 2018,3:99.

Figure 3. Possible physiological pathway in 24-hydroxylase deficient patients.